Senseonics has managed to raise an additional $20 million of private equity financing, while getting a new Vice President of Global Sales and Marketing – Mirasol Panlilio, who used to work at Abbott Diabetes Care and LifeScan.
Current investors Anthem Capital, Delphi Ventures, Greenspring Associates, Healthcare Ventures, New Enterprise Associates and other strategic partners all participated in the financing round.
The privately held company is focused on the development and commercialization of the first fully implantable, long-term continuous glucose monitoring (CGM) system. It plans to use the fresh cash to continue on this path that includes completing pivotal trials in Europe, obtaining CE mark, and initiating IDE trials in the United States. Said trials are expected to be completed at seven European sites before the end of summer.